Biotech & Healthcare
“Heavy Friday” Vista Partners Daily Market Recap 10/18/19
The market traded in the red today as a few issues were feeling a bit heavy. Johnson & Johnson (JNJ) with the headlines swirling about their baby powder which was apparently found to have traces of asbestos, Boeing (BA) with a report that surfaced suggesting that they may have misled the...
Oct 18, 2019
View Article
“Splash Of Green” Vista Partners Daily Market Recap 10/17/19
It was a splash of green for all across the board in the markets today as it pointed to a number of better than expected earnings reports and news from across the pond that a Brexit deal may be in the works. The S&P 500 ended today's session up by 8.26 points or .28% as it closed at 2,99...
Oct 17, 2019
View Article
J&J Exceeds Q3 Expectations/Raises Full-Year Forecasts In the Face Of Legal Issues
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. On Tuesday, Johnson & Johnson reported their successful Q3 earnings, confirming that they h...
Oct 17, 2019
View Article
“Mixed At Best” Vista Partners Daily Market Recap 10/16/19
The S&P 500 ended today's session down by 5.99 points or .2% as it closed at 2,989.69 just shy of the 3k level. The Dow lost 22.82 points closing over the 27k level at 27,001.98 down by .08%. The tech-heavy Nasdaq Composite closed above the 8k mark closing at 8,124.18 down .30% or 24...
Oct 16, 2019
View Article
The Dr. Susan Love Research Foundation, A “Major” Research University & Atossa Genetics (ATOS) Are Collaborating On Phase 2 Study of Intraductal Microcatheter Technology In Breast Cancer
The Dr. Susan Love Foundation for Breast Cancer Research's mission is to end breast cancer. It challenges the status quo to end breast cancer and improve the lives of people impacted by it now through education and advocacy. The Foundation drives collaborative, cutting-edge research with nontraditio...
Oct 16, 2019
View Article
UnitedHealth Group (UNH) Releases Its Q3 Analyst Beating Earnings Report
UnitedHealth Group Incorporated (UNH) declared its Q3 earnings report ending Sep 30th, on Tuesday exceeding analysts' expectations and raising its 2019 earnings forecast to 14.90 to $15 per share, in comparison to an earlier forecast of between $14.70 and $14.90, as per reports. UNH's revenues sa...
Oct 17, 2019
View Article
“A Fresh Wave Of Earnings” Vista Partners Daily Market Recap 10/15/19
Today, a wave of earnings kicked into high gear today which seemed to block out the ongoing trials and tribulations of the US-China trade war and we managed to have a very positive day in the markets. From the Dow 30, Johnson & Johnson (JNJ) reported earnings of $2.12, beating estimates ...
Oct 15, 2019
View Article
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia
Steven Quay received an M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over...
Oct 14, 2019
View Article
“Simply Red Columbus” Vista Partners Daily Market Recap 10/14/19
Today felt like a day where many were hiding or trying to hide in the US as schools, banks, and a few other companies celebrated the Columbus Day holiday but there is no rest for the wicked as the markets were open. It was lighter than normal volume day as many did play a bit of hookey and m...
Oct 14, 2019
View Article
Creator Of Alternative Infertility Treatments INVO Bioscience Hires NEW CEO Steven Shum
Infertility is “the inability to conceive after 12 months.” This means that a couple is not able to become pregnant after a year of trying. However, for women aged 35 and older, the inability to conceive after 6 months is generally considered infertility. According to fertilitycenter.com, the ab...
Oct 14, 2019
View Article
3M Acquires Acelity, Inc.
Reportedly, 3M (MMM) has completed the acquisition of Acelity, Inc., a leading global medical technology and its worldwide KCI subsidiaries for a total enterprise value of approximately $6.7 billion inclusive of debt and other adjustments. The deal was advised by Apax Partners along with controlled ...
Oct 17, 2019
View Article
Pfizer Shares Results Of Phase 3 Data For Abrocitinib In Moderate To Severe Atopic Dermatitis
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® ...
Oct 17, 2019
View Article
J&J Ordered To Pay Record Amount For Its Antipsychotic Drug Believed To Have Caused Gynecomastia
Reportedly, Johnson & Johnson has been asked to pay $8 billion as penalty charges to Nicholas Murray,who previously won $680,000 over his claims where J&J failed to alert young men over usage of its antipsychotic drug Risperdal causing gynecomastia, growth enlargement of male breasts, in a v...
Oct 14, 2019
View Article
“Optimistic Market Music” Vista Partners Daily Market Recap 10/11/19
The optimism and sweet tune or news that the US-China 'partial' trade deal was in play, imminent and apparently agreed to today fueled the market throughout as it reached mid-session highs. The Dow was up over 500 points at one point before tailing off into the close. We should also mentio...
Oct 11, 2019
View Article
“Partial To Green” Vista Partners Daily Market Recap 10/10/19
The US-China trade wars were squarely in the markets' line of view again today. An optimistic understanding flew around the "www" today that at least a partial agreement with China may be in the cards. A meeting with President Trump and China's Vice Premier, Liu He, also had wings and th...
Oct 10, 2019
View Article
Walmart Launches Low-Cost Healthcare Program For Its Employees To Curb Its Healthcare Costs
The retail giant, Walmart Stores, Inc. (WMT) with 1.4 million in its collective workforce in the U.S is launching various healthcare pilot programs for its U.S employees starting January 1 in an attempt to cut healthcare costs which are a major expense for the retailer after wages, as per reports. ...
Oct 12, 2019
View Article
“Open…?” Vista Partners Daily Market Recap 10/9/19
All the markets apparently needed today was one word from the Chinese regarding the trade wars, "open", and the game was back on. Mind you that the Chinese only suggested that they were open to a partial deal but again the markets these days seem to hold on to what they want to here and tod...
Oct 09, 2019
View Article
Merck’s Two Applications For DIFICID® Drug On Review Priority List Of FDA
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the le...
Oct 13, 2019
View Article
“Expanding” Vista Partners Daily Market Recap 10/8/19
"Expanding" seemed to be the word of the day today. First, it was widely reported that the U.S. Commerce Department expanded its Entity List" with 28 additional Chinese firms as they had played some role in "fostering violations of human rights" against a Muslim minority in China. A Beijing...
Oct 08, 2019
View Article
Pfizer Presents Interim Analysis From Phase 3 Trial In Advanced BRAFV600E-Mutant Metastatic Colorectal Cancer
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® ...
Oct 10, 2019
View Article
“Trade, Cut, Confusion” Vista Partners Daily Market Recap 10/7/19
With Warner Brothers' new supervillain movie Joker experiencing an opening weekend with $247M in global ticket sales you might think all is well as headlines flew around the world today preaching its success. However, a Bloomberg article did its best to counter these good feelings with anoth...
Oct 07, 2019
View Article
“Fragile Wings!” Vista Partners Daily Market Recap 10/4/19
We received a good ending to a volatile week that certainly left many of our heads still spinning. As has been the custom this week the markets seem to be riding up and down on the fragile wings of each piece of economic data more than normal. Today, the economic schedule confirmed that the ...
Oct 04, 2019
View Article
“Rate Cut…!” Vista Partners Daily Market Recap 10/3/19
On Thursday, more economic data was released and hit the markets at 7 am pacific. The markets took an initial nosedive prior to recovering into the close after we received the ISM Non-Manufacturing Index report for September which dropped to 52.6% from the 56.4% mark in August. Layering this...
Oct 03, 2019
View Article
INVO Bioscience Will Exhibit At The World Congress of the International Society for In-Vitro Fertilization (ISIVF) on October 24-26 in Barcelona
Sarasota-based INVO Bioscience, Inc. (IVOB), a US publicly-traded medical device company that was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, will exhibit at the 20th World Congress of the International Society for In-Vitro Fertilization (ISIVF) on October 24-26, 2...
Oct 09, 2019
View Article
INVO Bioscience Will Exhibit at American Society for Reproductive Medicine (ASRM) 2019 In Philadelphia Oct. 12-16
Sarasota-based INVO Bioscience, Inc. (IVOB), a US publicly-traded medical device company that was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, will exhibit at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress October 12-16, 2019 in Phi...
Oct 02, 2019
View Article
“Double Down?” Vista Partners Daily Market Recap 10/2/19
No sir!... I am not suggesting you double down on the stock market or anything at this point, however, we did double our consecutive down days today as the markets got stung again & proceeded fall significantly across the board once again. The downward move came in reaction to addition...
Oct 02, 2019
View Article
Walgreen Collaborates With Novant Health To Expand Retail Health Care In North Carolina
Walgreen Boots Alliance (WBA), a relatively recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. Reportedly, Walgreens and Novant Health, a leading healt...
Oct 04, 2019
View Article
“Manufacturing Woes” Vista Partners Daily Market Recap 10/1/19
Today, the markets suffered through a bit of negative economic news that came out of the manufacturing sector that seemed to surprise and bring forth woes for many on this first day of October. The Institute for Supply Management’s factory index was reported to have slipped to 47.8 in Sept...
Oct 01, 2019
View Article
Breast Cancer Focused Atossa (ATOS) Successfully Meets All Objectives In Phase 1 Study Today
Legislation has been recently enacted in approximately 35 states requiring that women be notified if they have mammographic breast density (MBD) and those notifications typically state that women with MBD have a higher risk of developing breast cancer, and that mammography may not be as effective in...
Sep 30, 2019
View Article
“Q3 Positively Ends” Vista Partners Daily Market Recap 9/30/19
Today, the markets ended Q3 on a positive swing after a US Treasury representative on Saturday followed up by White House trade advisor Peter Navarro essentially refuted Friday's Bloomberg story that stated that the Trump administration is considering limits to US investors' flows into Chin...
Sep 30, 2019
View Article
“China Limits” Vista Partners Daily Market Recap 9/27/19
The markets ended the week on a downward slope as we continued to get less than positive news from many fronts spearheaded by the trade wars that continue to bring uncertainty and weigh on the markets this week. Bloomberg ran a story today stating that the Trump administration is considering...
Sep 27, 2019
View Article
“Adrift” Vista Partners Daily Market Recap 9/26/19
The markets seemed to be without a great deal of conviction and/or just adrift but lower today in a sea of headlines related to trade wars (Huawei again), tariffs, impeachment, whistleblower action more positive economic reports, and historically low jobless claims. The S&P 500 ended tod...
Sep 26, 2019
View Article
“New Homes Push” Vista Partners Daily Market Recap 9/25/19
After yesterday's somewhat somber "impeachment inquiry' news we started out a bit sluggish in the markets & understandably so. Then the market was given some notes from President Trump's call with Ukrainian President Zelensky and the trade wars to a bit of back seat to the new home sales...
Sep 25, 2019
View Article
“Somber” Vista Partners Daily Market Recap 9/24/19
It was sobering if not a somber day in the markets and throughout the US as many seemed to focus on the negative and uncertainty rather than what came about that was positive. In the economy, we learned that the Conference Board's Consumer Confidence Index for September dropped to 125.1 whi...
Sep 24, 2019
View Article
“Eyes On German PMI” Vista Partners Daily Market Recap 9/23/19
All eyes were on the German PMI situation on Monday as it showed that the German economy, the European union's largest economy, had contracted in September & confirming that the manufacturing and service sectors worsened. September’s IHS Manufacturing PMI for Germany read 41.4, sign...
Sep 23, 2019
View Article
Merck’s Blockbuster Keytruda Plus Chemotherapy Demonstrates Improvement In Triple-Negative Breast Cancer
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at th...
Sep 25, 2019
View Article
“No To Montana?” Vista Partners Daily Market Recap 9/20/19
Who says no to visiting Montana this time of year? It's so beautiful & peaceful this time of year, correct? Well...the Chinese that's who. The Chinese agricultural delegates, in fact, dared to say "no" to their previous invite and plan to visit Montana-based farms today. The markets took this ...
Sep 20, 2019
View Article
Fate Therapeutics (FATE) Closes Underwritten Public Offering For Proceeds of ~$173.1 million
San Diego-based Fate Therapeutics (FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal...
Sep 20, 2019
View Article
“Ho-Hum” Vista Partners Daily Market Recap 9/19/19
After yesterday's "big decision" was revealed where the Fed met again and voted 7-3 to raise interest rates for the second time this year by another .25 basis points to 1.75-2%, we experienced a bit of a "ho-hum" sort of day as the markets pretty much stayed in place on relatively low volume. The ...
Sep 19, 2019
View Article
“7-3 Vote” Vista Partners Daily Market Recap 9/18/19
Well, we got it, folks. Yes, the Fed met again today and voted 7-3 to raise interest rates for the second time this year by another .25 basis points to 1.75-2%. This move was as the market had widely expected. President Trump also continued to tell the Fed tht they have it all wrong stating "Jay Pow...
Sep 18, 2019
View Article
“Fed Up Next” Vista Partners Daily Market Recap 9/17/19
The broad markets finished higher again today, except for the Russell 2000, the small-cap stock market index representing the bottom 2,000 stocks in the Russell 3000 Index which moved lower by .40% or 6.31 points closing at 1,578.29. the overall positive move came about with the impending interest...
Sep 17, 2019
View Article
Merck’s Treatment For Rare NSCLC Gains FDA Breakthrough Therapy Designation
Reportedly, Merck KgaA’s tepotinib, a treatment for the MET exon14 skipping mutation in the genetic makeup of a lung tumor, has been awarded the U.S. Food and Drug Administration's breakthrough therapy designation. Breakthrough therapy is a United States Food and Drug Administration designatio...
Sep 12, 2019
View Article
Atossa Genetics Completes Enrollment, Dosing & Expects to Report Preliminary Results For Phase 1 Study Of Oral Endoxifin in Next 30 Days
It is estimated that approximately ten million women in the United States have MBD, for which there is no FDA-approved treatment. Although oral tamoxifen is approved to prevent breast cancer in “high-risk” women, it is used by less than 5 percent of women with an increased risk of developing...
Sep 03, 2019
View Article
Amgen Gears Up To Own Worldwide Rights Of Otezla®
Reportedly, Amgen (AMGN) has entered in an agreement with Celgene Corporation (CELG) to acquire the worldwide rights of the only oral, a non-biologic treatment for psoriasis and psoriatic arthritis, Otezla. The acquisition is set to proceed for an amount of $13.4 billion in cash, or approximate...
Aug 29, 2019
View Article
Record Q2 Announced By Fertility Med Device Firm INVO Bioscience- (Increase of 498%)
Sarasota, FL-based INVO Bioscience, Inc. (IVOB), a medical device company that was granted FDA clearance for its Intravaginal Culture System, INVOcell®, released its financial results for Q2 2019. The INVO Procedure is a new and effective fertility treatment option allowing fertilization and...
Aug 14, 2019
View Article
Seattle’s Atossa Genetics (ATOS) Published Q2 Financial Results & Company Update
Seattle-based Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today published their financial results for Q2, 2019 and provided an update on recent company developments....
Aug 13, 2019
View Article
Atossa Genetics CEO Steven Quay Gives Tedx Talk Regarding Relationship of Dense Breast Tissue & Breast Cancer Risk
Steven Quay is the founder of Seattle-based Atossa Genetics, Inc., dedicated to breast cancer prevention. He received a Ph.D. in Biological Chemistry and a M.D. from the University of Michigan, a postdoc at MIT and Harvard, and he was a faculty member at Stanford Medical School. His contribution...
Jul 30, 2019
View Article
Pfizer Spinning Combined Off-Patent Drug Business With Generic Drugmaker Mylan NV
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer annonced that it will combinen off-Patent Drug Business, Upjohn, with generic drugmaker Mylan NV. This combination will surfacd on t...
Jul 31, 2019
View Article
Walgreen Growing Kaleo Partnership Amid National Shortage Of Allergy Shots
Walgreen Boots Alliance (WBA), a recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. Last week, Walgreens Boots Alliance Inc announced that it is ex...
Jul 16, 2019
View Article
J&J Continuing Research For Mid-Stage HIV Vaccine
As per reports, Johnson & Johnson (JNJ) is staged to move forward with a late-stage study of an investigational vaccine for Human Immunodeficiency Virus (HIV), a condition that weakens the immune system of the body in countries like America and Europe. The company is continuing its research...
Jul 14, 2019
View Article
Microsoft Partnering With Providence St. Joseph Health To Move to the Cloud
Redmond, Washington-based American multinational technology company Microsoft (MSFT) develops, manufactures, licenses, supports and sells computer software, consumer electronics, personal computers, and related services. Recently, Providence St. Joseph Health and Microsoft reportedly entered ...
Jul 10, 2019
View Article
MARK THESE DATES ALERT: Biohaven Pharmaceutical Holding Company (BHVN) July 11-14, 2019
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectu...
Jul 09, 2019
View Article
Pfizer Presented Data On Duchenne Muscular Dystrophy (DMD) In Florida
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Pfizer Inc introduced the initial Phase 1b clinical data on PF-06939926 at 25th Annual Parent Project Muscular Dystrophy (PPMD) Connect Conference...
Jul 05, 2019
View Article
Atossa Genetics Reports Preliminary Analysis From Phase 2 – “Proprietary Topical Endoxifen Significantly Reduced Breast Density”
Legislation has been recently enacted in approximately 35 states requiring that women be notified if they have Mammographic Breast Density (MBD) and those notifications typically state that women with MBD have a higher risk of developing breast cancer, and that mammography may not be as effect...
Jun 27, 2019
View Article
Pfizer To Acquire Array BioPharma Seeking to Strengthen Its Innovative Biopharmaceutical Business
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. This week, Pfizer Inc announced to acquire Array BioPharma Inc in a definitive merger agreement. Array BioPharma Inc, a biopharmaceutical company ...
Jun 24, 2019
View Article
Low-Cost Fertility Treatment Firm INVO Bioscience Hires Former Cooper Surgical Executive
On a worldwide basis, there are approximately 150 million infertile couples. Approximately 1.5 million IVF cycles are performed annually corresponding to approximately 1% of the infertile couples worldwide. Including IUI (another 1% worldwide), this represents an approximate $6.6 billion worldwi...
Jun 20, 2019
View Article
Antisense Focused Stoke Therapeutics’ IPO Is Off To A Great Start Today!
Bedford, Massachusetts-based Stoke Therapeutics is a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. They develop antisense oligonucleotide medicines that increase gene expression to treat genetic epile...
Jun 19, 2019
View Article
Exciting FDA Approval Gained For Merck’s Keytruda in Treatment of Head & Neck Cancer
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at th...
Jun 17, 2019
View Article
Merck Announces The Acquisition Of TGFβ Focused Tilos Therapeutics
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be a...
Jun 12, 2019
View Article
INSIDER BUYING ALERT: Community Health Systems, Inc. (CYH) Director Michael Dinkins
One of the largest publicly traded hospital companies in the US and a leading operator of acute care hospitals in communities across the country, Community Health Systems, Inc (CYH) hit an intraday high of $3.06/share & a low of $2.895/share today and closed the day at $2.93/share down 4.56% on...
May 29, 2019
View Article
Oklahoma Attorney General Mike Hunter Files Multibillion-dollar “Opioid” Case Against J&J
Reportedly Johnson & Johnson (JNJ) has been accused of using deceitful methods to encourage the over-use of opioid painkillers that has led to a U.S. opioid epidemic. Mike Hunter, Oklahoma Attorney General recently filed a multi-billion dollar case demanding J&J to pay for helping cau...
May 29, 2019
View Article
Travelers Now Targeting Medical Tech, Pharmaceuticals & Digital Health Firms With Life Sciences Offering
Recently, The Travelers Companies, Inc. (TRV) was reported to have introduced a complete Life Sciences practice offering insurance and risk management solution in pharmaceuticals, digital health and medical devices including health care IT, medical software, and telemedicine. Their program is ...
May 28, 2019
View Article
FDA Approves Novartis AG’s PI3K Inhibitor Treatment For Advanced Breast Cancer In Men & Women
According to multiple reports on Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s PI3K inhibitor treatment, a drug called alpelisib, which will be marketed under the brand name Piqray. Piqray is approved to be administered in combination with hormone therapy for post...
May 25, 2019
View Article
Merck Acquiring Peloton Therapeutics Pushing to Diversify Offerings In Cancer
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at ...
May 23, 2019
View Article
INSIDER BUYING ALERT: Community Health Systems, Inc. (CYH) Director James S. Ely III
One of the largest publicly traded hospital companies in the US and a leading operator of acute care hospitals in communities across the country, Community Health Systems, Inc (CYH) hit an intraday high of $3.29/share & a low of $3.115 today and closed the day at $3.28 up nicely 3.14% on 1.23 m...
May 20, 2019
View Article
Seattle’s Atossa Provides Q1 Results & Progress Developments
Seattle based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. On Monday after the market close Atossa announced their financial results for the quarter ended Ma...
May 14, 2019
View Article
Australian Competition and Consumer Commission Pushes Forward GSK-Pfizer Consumer Healthcare Business
The GlaxoSmithKline' deal seeking to purchase & combine Pfizer's consumer healthcare business with their own has recently received approval from Australia’s antitrust regulator recently called the Australian Competition and Consumer Commission (ACCC.) It was reported that the ACCC anti...
May 14, 2019
View Article
UnitedHealth Group Initiates “Low Cost” Maternity Care Programs
Increasing healthcare costs has become a major concern in the United States especially when it comes to maternity costs from prenatal to postpartum care which has been surging. Now UnitedHealth Group Incorporated (UNH) has come up with a health care plan to cut maternity cost where partner hospita...
May 09, 2019
View Article
Pfizer’s Drug For Treating Fatal Heart Disease Gains FDA Approval
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Pfizer Inc.'s oral drug tafamidis effective in treating “transthyretin amyloid cardiomyopathy”, a rare and fatal heart disease recently gained appr...
May 09, 2019
View Article
United Healthcare Received $4.5M Funded 5-year Accountable Health Communities Award In Hawaii
United Healthcare recently received a $4.5 million funded 5-year Accountable Health Communities award from the Centers for Medicare & Medicaid Services (CMS) to improve social related health services in Oahu, Hawaii. The program seeks to partner with Waianae Coast Comprehensive Health Center, ...
May 02, 2019
View Article
“A Twenty-First Century Approach: From Primary Prevention to Intraductal Immunotherapy”
Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced this week that Steven C. Quay, M.D., Ph.D., Atossa’s President, and CEO, provided an update on the Company...
Apr 26, 2019
View Article
Hope For Restoring Young Cancer Patient’s Fertility Emerges After New Research
Researchers with the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute, have successfully restored fertility to non-human primate model of childhood cancer, creating hope that the same process may be successful in humans. The researchers were able to cryopreserve ...
May 03, 2019
View Article
FDA Approves Johnson & Johnson’s Advanced Bladder Cancer Drug
According to The American Cancer Society’s website estimates for bladder cancer in the United States for 2019 are about 80,470 new cases of bladder cancer (about 61,700 in men and 18,770 in women and about 17,670 deaths from bladder cancer (about 12,870 in men and 4,800 in women. The rates of n...
Apr 15, 2019
View Article
UnitedHealthcare Widens Collaboration With Care Providers In More Than 30 States
Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company's UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employ...
Apr 15, 2019
View Article
Walgreens & VillageMD Integrating Adult Primary Health Care & Pharmacy Offering In Houston
Leading Primary health care provider VillageMD and Walgreen announced that they are coming together to offer valuable primary health care services under the brand “Village Medical at Walgreens” to adult patients within the Houston community. Initially, VillageMD is to set up health care clin...
Apr 12, 2019
View Article
Breast Cancer Treatment Innovator Atossa Genetics Announced Year End 2018 Financial Results & Provided Business Update This Week
Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Today Atossa announced year-end 2018 financial results and provided an update on recent company de...
Mar 28, 2019
View Article
Institutional Review Board Approves Use of Atossa’s Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS) ("Atossa") is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Shares of Atossa jumped to a high of $4.865 today and are currently trading at $4.14 u...
Mar 26, 2019
View Article
Breast Cancer Treatment Focused Biotech Atossa Genetics (NASDAQ: ATOS) Raises $10 Million – Jumps Again!
Atossa Genetics (ATOS) a Seattle-based biotech firm focused on developing treatments for breast cancer had another wonderful day as it jumped up 24.47% closing at $4.40 on 24.84 Million shares of trading. This increase came about today as ATOS announced that on March 14th and 15th, 2019, it rece...
Mar 18, 2019
View Article
MARKET ALERT: Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
Sometimes called "compassionate use," expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical tri...
Mar 14, 2019
View Article
INVO Bioscience Partners with “Egg Whisperer” To Launch San Francisco Bay Area Embryology Center
MEDFORD, MA-based INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experi...
Mar 13, 2019
View Article
Developer of Programmed Cellular Immunotherapies Fate Therapeutics (NASDAQ: FATE) Reports Q4 & Full Year 2018 Financial Results – Highlights Operational Progress
San Diego-based Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31...
Mar 05, 2019
View Article
American Society of Breast Surgeons Now Recommends Genetic Testing for All Breast Cancer Patients
The American Society of Breast Surgeons released new recommendations last Thursday that suggested genetic testing for inherited mutations should be offered to all breast cancer patients. These recommendations are in somewhat of opposition with those offered by the National Comprehensive Cancer Ne...
Feb 19, 2019
View Article
MARKET ALERT: Atossa Updates Status of Pre-menopausal, Estrogen-receptor Positive Breast Cancer Patient
Sometimes called "compassionate use," expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical tri...
Feb 08, 2019
View Article
Fertility Treatment Innovator INVO Bioscience Adds Michael J. Campbell as COO/VP of Business Development
Medford, MA-based INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation tha...
Feb 06, 2019
View Article
Breast Cancer Treatment Innovator Atossa Genetics’ CEO Issues Annual Letter to Shareholders Highlighting Strategy for 2019
Seattle-based Atossa Genetics Inc. (ATOS) a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions issued the following letter from Dr. Steven C. Quay, President, and CEO, to Atossa shareholders: ...
Jan 29, 2019
View Article
INVO Bioscience & Ferring Pharmaceuticals Close Exclusive U.S. Licensing Agreement to Commercialize INVOcell™ For Treatment of Infertility
INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure, is a disruptive new technology & is a revolutionary in vivo method of vaginal incubation that offers patients a more natural a...
Jan 28, 2019
View Article
Lilly Paying $8 Billion for Loxo Oncology During JPM2019
JPMorgan Healthcare Conference week brings forth another sizable deal as Lilly (LLY) will commence a tender offer to acquire all outstanding shares of Loxo Oncology (LOXO) for a purchase price of $235.00 per share in cash, or approximately $8.0 billion. Lilly is reported to be making a bet on a ...
Jan 07, 2019
View Article
Largest Pharmaceutical Deal Ever to Take Place Between Bristol-Myers and Celgene
In the biggest pharmaceutical deal ever, Bristol-Myers Squibb will buy Celgene for $74 billion, combining two the largest cancer drug businesses in the world. Wall Street analysts have questioned whether this merge would solve the individual challenges the two companies face. The companies have st...
Jan 07, 2019
View Article
